PMID- 24861909
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20231120
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 74
IP  - 8
DP  - 2014 Jun
TI  - Albiglutide: first global approval.
PG  - 929-38
LID - 10.1007/s40265-014-0228-2 [doi]
AB  - Albiglutide (Eperzan(R) [EU]; Tanzeum [US]), a glucagon-like peptide 1 receptor 
      agonist, has been developed by GlaxoSmithKline for the treatment of type 2 
      diabetes mellitus (T2DM). Albiglutide has received its first global approval in 
      this indication in the EU, for use in combination with other antihyperglycaemic 
      agents, including basal insulin, when these drugs and diet and exercise do not 
      provide adequate glycaemic control, and as monotherapy in patients unable to take 
      metformin due to contraindications or intolerance when diet and exercise alone do 
      not provide adequate glycaemic control. Albiglutide has subsequently been 
      approved for the second-line or later treatment of T2DM as an adjunct to diet and 
      exercise in the US. This article summarizes the milestones in the development of 
      albiglutide leading to this first approval for the treatment of T2DM.
FAU - Poole, Raewyn M
AU  - Poole RM
AD  - Adis, Auckland, New Zealand.
FAU - Nowlan, Mary L
AU  - Nowlan ML
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Receptors, Glucagon)
RN  - 5E7U48495E (rGLP-1 protein)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Approval
MH  - Drug Therapy, Combination
MH  - Glucagon-Like Peptide 1/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Receptors, Glucagon/agonists
EDAT- 2014/05/28 06:00
MHDA- 2015/06/16 06:00
CRDT- 2014/05/28 06:00
PHST- 2014/05/28 06:00 [entrez]
PHST- 2014/05/28 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - 10.1007/s40265-014-0228-2 [doi]
PST - ppublish
SO  - Drugs. 2014 Jun;74(8):929-38. doi: 10.1007/s40265-014-0228-2.